These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22431777)

  • 1. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
    Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
    Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
    Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
    J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
    Chon SY; Sambrano BL; Geddes ER
    J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse events during vemurafenib therapy.
    Chandrakumar SF; Yeung J
    J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vemurafenib (Zelboraf) in the therapy of melanoma].
    Liszkay G
    Magy Onkol; 2013 Jun; 57(2):110-3. PubMed ID: 23795356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of vemurafenib-induced keratosis pilaris-like eruption.
    Wang CM; Fleming KF; Hsu S
    Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
    Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
    J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
    LaPresto L; Cranmer L; Morrison L; Erickson CP; Curiel-Lewandrowski C
    JAMA Dermatol; 2013 Mar; 149(3):279-81. PubMed ID: 23552479
    [No Abstract]   [Full Text] [Related]  

  • 14. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eruptive squamous cell carcinomas after vemurafenib therapy.
    Mays R; Curry J; Kim K; Tsai K; Arora A; Khan F; Ramirez-Fort M; Ciurea A
    J Cutan Med Surg; 2013; 17(6):419-22. PubMed ID: 24138980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
    Kent R; Glorioso S; Nordberg ML
    J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous side effects of vemurafenib: a case report and discussion.
    Shea SM; Boyd K; Patterson J
    Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.